Clinique Pasteur
- Address
- lock Available on a paid plan
Clinique Pasteur - Comprehensive Oncology and Cardiovascular Research Center
Clinique Pasteur is a leading medical research institution with extensive expertise in oncology and cardiovascular medicine. The center demonstrates particular strength in precision oncology trials, conducting advanced studies across multiple cancer types including breast, prostate, head and neck, cervical, pancreatic, and gastrointestinal malignancies. Their research encompasses innovative approaches combining immunotherapy, targeted therapies, and radiotherapy, with a focus on personalized treatment strategies.
- Advanced breast cancer research including hormone receptor-positive disease, triple-negative breast cancer, and genomic-guided treatment strategies
- Prostate cancer studies investigating oligometastatic disease, biochemical recurrence, and novel androgen receptor inhibitors
- Cardiovascular interventions including TAVI, atrial fibrillation management, renal denervation for hypertension, and antithrombotic therapy optimization
- Gastrointestinal oncology trials focusing on colorectal, pancreatic, cervical, and anal cancers with chemotherapy intensification approaches
The center's comprehensive portfolio includes Phase II and III clinical trials evaluating novel therapeutic combinations, adaptive treatment strategies, and risk-stratified approaches. Notable research areas include the use of circulating tumor DNA (ctDNA) for treatment decision-making, biomarker-driven patient selection, and the integration of advanced imaging techniques. Clinique Pasteur also conducts important studies in metabolic liver diseases such as NASH/MASH, primary biliary cholangitis, and cardiac surgery-associated complications, demonstrating their multidisciplinary research capabilities across oncology, hepatology, and cardiovascular medicine.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 11 therapeutic areas and 15 of 119 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 95 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Clinique Pasteur
lock Showing 1 of 56 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A double-blind randomized, Phase III study of radiotherapy combined with cetuXimab + Xevinapant compared to radiotherapy combined with cetuximab (Standard of care) + placebo in patients with Locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN), unfit for high-dose cisplatin (XXL study) | Groupe Oncologie Radiotherapie Tete Cou | Phase III | Not Recruiting | Dec 2023 | Sep 2024 |
IMP list
lock Showing 1 of 119 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 5 | Unknown | 2020-07-17 | 2025-11-26 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.